BioArctic AB
B9A
Company Profile
Business description
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
Contact
Warfvinges vag 35
StockholmSE-112 51
SWET: +46 86956930
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
141
Stocks News & Analysis
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
We think this improves Nvidia’s position within the open-source community.
stocks
Anthropic’s IPO will be huge—and risky. Here are the challenges investors should watch
Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,197.80 | 52.80 | -0.57% |
| CAC 40 | 8,286.40 | 5.77 | 0.07% |
| DAX 40 | 26,003.32 | 163.99 | 0.63% |
| Dow JONES (US) | 53,686.11 | 624.16 | 1.18% |
| FTSE 100 | 10,831.52 | 75.07 | 0.70% |
| HKSE | 25,734.82 | 521.51 | 2.07% |
| NASDAQ | 26,584.06 | 366.23 | 1.40% |
| Nikkei 225 | 65,106.60 | 892.12 | 1.39% |
| NZX 50 Index | 13,974.18 | 128.00 | 0.92% |
| S&P 500 | 7,747.71 | 81.11 | 1.06% |
| S&P/ASX 200 | 9,008.40 | 61.80 | -0.68% |
| SSE Composite Index | 3,967.05 | 24.96 | 0.63% |